Loading...

Call for Panelists

4D Meets AI is proud to highlight active investors and early-stage founders advancing drugs, devices, diagnostics, and digital health through the power of AI. Innovative, smart technology with creative applications take center stage alongside insights around how to navigate the early-stage investment ecosystem.

This March, 4D Meets AI is hosting panels where active investors in the space are joined by their portfolio companies to discuss funding, partnerships, and the future of AI in life science and healthcare. Join us for four live panels, each delving into one of the 4Ds.

Are you an investor, actively working with early-stage AI technology, with a portfolio company to highlight? Apply to join a panel below!

Join a Panel

Thursday, March 18 | 9 AM EST
Panelists to be Announced

Thursday, March 18 | 2 PM EST

Additional Panelists to be Announced

Jean Anne Booth, CEO, UnaliWear (Entrepreneur)
A serial entrepreneur with two successful exits, Jean Anne Booth has 30 years of experience in high technology, and has raised over $100M in venture capital for her startup companies. Now on her fourth startup, UnaliWear’s Kanega watch has been named by focus groups to be a “wearable OnStar for People” because it provides discreet support for falls, medication reminders, and a guard against wandering in a voice-first, classically-styled watch. With a patented quick-swap battery system in the band, wearers never have to take the Kanega watch off to charge, and patented AI learns the wearer’s lifestyle to provide predictive, pre-emptive support to independent but vulnerable populations. Jean Anne was previously the founder of Luminary Micro, the creators of the Stellaris® microcontroller (MCU) platform and the lead partner and first to market with ARM® Cortex™-M3-based microcontroller solutions. Luminary Micro was acquired by Texas Instruments in May 2009, and was one of the top 5 venture-backed acquisitions in 2009. Jean Anne retired from TI in 2012 after serving as the General Manager for TI’s Stellaris family of products. Jean Anne was also a founder at Intrinsity, which was sold to Apple in April 2010. Her first startup experience was at Exponential Technology, the creators of a 533 MHz BiCMOS PowerPC microprocessor. Early in her career, Jean Anne worked with AMD’s embedded microprocessor products for 10 years in a number of management, marketing, and engineering roles, and in R&D at Fisher Controls. Jean Anne holds a BSEE from the University of Texas and an MSCE degree from National Technical University.

Terence Craig, Chief Investment Officer, The Impact Seat (Investor)
Terence Craig is the Chief Investment Officer for The Impact Seat, one of the leading independent investors in high growth technology companies led by women, especially women of color. At The Impact Seat, Terence leads investment activities and provides post-investment support for over 60 portfolio companies and monitors their LP investment in several venture funds. An experienced technologist, speaker and author, Terence has founded multiple companies and has served as the Chief Technology Officer at multiple venture-backed companies including the Mayfield funded Consensys Software and several pioneering enterprise and Big Data software companies. Terence was one of the earliest Black CEOs and founders to raise venture capital (way back in 1998), and he uses that experience and expertise to improve the startup ecosystem. His goal has been to support other “non-traditional” founders in navigating the startup landscape. His efforts to increase inclusion in the startup ecosystem led Terence to join the executive team at Astia Angels, an international angel group focused on investing in high-growth companies with women on the leadership team. During his time at Astia, Terence ran a pilot investment program to support Women of Color called the Representation Program, funded by strategic corporate funders. The program was such a success that Astia has now made it a permanent part of their investment platform. Terence’s book, Privacy & Big Data , has been translated into several languages and is currently available for purchase on numerous platforms such as Amazon, Barnes and Noble and Google Books.

Friday, March 19 | 9 AM EST

Moderator to be Announced

Michele Colucci, JD, CEO & Managing Partner, Digital Dx Ventures (Investor)
Michele Colucci is a venture capital thought leader, lawyer, investor, serial entrepreneur, and philanthropist. She has authored five patents in the technology space and founded companies in the legal, technology, retail, and entertainment spaces. Her extensive experience operating in highly regulated verticals has focused on issues from management to legal. As a venture capitalist focused on med-tech, Colucci is committed to impacting the health field by investing in companies that enable doctors to make better diagnostic decisions through the application of AI and big data. She is a member of the board of directors of public and private firms including Global Indemnity Group, Nephrosant, Optina Diagnostics, Prime Genomics, and Trayt. She has been a frequent guest lecturer at Stanford University’s School of Engineering. In 2017, Colucci was named West Coast Ambassador by the Nobel Laureate Foundation. She earned her BA and JD from Georgetown University and an MFA from the AFI. Colucci speaks three languages and currently resides in Silicon Valley with her four children.

Chris Kent, PhD, President & CEO, ODS Medical (Entrepreneur)
Chris is the founding CEO of ODS Medical Inc, a medical technology company dedicated to pushing the limits of cancer detection by developing optical biopsy tools based on machine learning and Raman spectroscopy. Prior to ODS Medical, he worked with his co-founder Dr. Kevin Petrecca, building a translational research program at the Montreal Neurological Institute focused on working with industry partners to accelerate the discovery and pre-clinical development of a wide variety of small molecules and biologics for treatment of brain cancers. He has published numerous peer-reviewed journal articles. Prior to his work at the MNI, Chris was involved with a start-up that specialized in the application of stimuli-responsive polymer materials to a wide range of industries. As Director of Business Development and IP strategy, he developed the company’s business model, leveraging strategic industry collaborations in sectors such as packaging, textiles, energy and life sciences, into a growing patent portfolio which through subsequent development and out-licensing deals grew the company’s revenue ten-fold.

David Lapointe, President & CEO, Optina Diagnostics (Entrepreneur)
An entrepreneur by nature with a keen eye for identifying opportunities, Mr. Lapointe boasts a proven capacity for combining his in-depth understanding of the market with the development of innovative technology. Results-oriented, his mission is to benefit the advancement of the healthcare industry with an ROI for stakeholders.

Neal Mody, Founder & Managing Director, Zoic Capital (Investor)
I’m obsessed with building great companies and focus on those life sciences that will affect humanity. Early in my career, I was fortunate enough to help scale Ambature, a materials science company in the field of superconductivity. When I started Ambature, I didn’t have any experience in materials science; nevertheless, I operated under the belief that the inventor’s idea was right. Fast forward a few years, by the time I left my role, we created over 200 patents with more than 3,700 unique claims, accounting for more than half patents in the field of superconductivity. After I left Ambature, I wanted to make a more significant impact in life sciences, and ultimately on humanity. Being driven by this social mission, I thought about starting a few companies simultaneously; however, after some back and forth, I ultimately concluded that starting a fund would better allow me to scale my efforts. Through Zoic Capital, my team and I help our portfolio companies and investors:

  • Develop large scale inclusive IP development strategy
  • Help connect and codevelop deals with potential strategic acquirers

We are currently the only US-based venture firm focused solely on investing in the seed stage of Medtech, we go through a rigorous vetting process with each investment opportunity to ensure that:

1. their technological developments represent at least a 10X improvement in the standard of care

2. their technology relies upon scientific mechanisms which are fully supported by published literature, independent trials, and personal observation

3. in most cases, they have unique hardware and IP coupled with unique software

4. the leadership team has the necessary combination of vision and experience to create a transformational company

5. has an initial regulatory approval on a short timeline, typically two to four years

If you want to learn more about Zoic, the types of companies we invest in, or if you’d like to talk about the market and feature on my podcast, feel free to get in touch with me via email: neal@zoiccapital.com

 



Friday, March 19 | 2 PM EST

Additional Panelists to be Announced

Esther Dyson, Executive Founder, Wellville (Investor)
Founder of Wellville and chairman of EDventure Holdings, Esther is an active angel investor, best-selling author, board member and advisor concentrating on emerging markets and technologies, new space and health. She sits on the boards of 23andMe and Voxiva (txt4baby), and is an investor in Crohnology, Eligible API, Keas, Omada Health, Sleepio, StartUp Health and Valkee, among others. From October 2008 to March of 2009, Esther lived in Star City outside Moscow, Russia, training as a backup cosmonaut.

 

Amit Garg, Managing Partner, Tau Ventures (Investor) 
I am currently Co-Founder and Managing Partner at Tau Ventures, a seed fund in Palo Alto focused on applied AI in digital health, automation (cars, drones, robots), and enterprise. Our 15 current investments include ArmorCode (application security), Biotia (analyze pathogen genomes to prevent hospital contamination), Blendid (robotic arm for making food), Cerby (cybersecurity to harness shadow IT), Elemental Machines (IoT to improve production of foods+drugs), FidoCure (treat cancer in dogs), Freedom Robotics (cloud platform for robotics), Infinitus (helping patients navigate healthcare), Iterative Scopes (computer vision for colon cancer), RapidDeploy (unified public safety), RubiconMD (referral service for primary care physicians), Signos (weight loss through glucose monitoring), Totient (cancer drug discovery), and two investments in stealth. I have been in Silicon Valley for 20 years — at Samsung NEXT Ventures where I seed-funded nuTonomy (self-driving cars, sold for $450M), co-founded a startup called HealthIQ (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures ($10B AUM), and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.

Jonathan Ng, CEO, Iterative Scopes (Entrepreneur) 
Jonathan Ng is a trained doctor from Singapore and the CEO of Iterative Scopes, an MIT healthcare startup that raises the standard of cancer treatment.